Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics (Nasdaq: VERA) granted equity inducement awards on June 2, 2026 under its 2024 Inducement Plan, pursuant to Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Summary

Vera Therapeutics (Nasdaq: VERA) granted equity inducement awards on June 2, 2026 under its 2024 Inducement Plan, pursuant to Nasdaq Listing Rule 5635(c)(4).

The awards cover 28,800 stock options at a $31.26 exercise price and 14,150 RSUs for ten new employees, vesting over four years.

Positive

• Inducement grants cover 28,800 stock options and 14,150 RSUs for new hires
• Four-year vesting schedules support employee retention and long-term alignment
• Stock option exercise price set at $31.26, matching June 2, 2026 closing price

Negative

• Equity awards represent potential dilution of 42,950 Class A common shares

Argus Jun 8 session

-1.67% close to close Open Argus

Details

News Market Reaction – VERA

In the Jun 8 session, VERA declined 1.67%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details equity inducement awards—stock options and RSUs—granted to new employees u...

Analysis

This announcement details equity inducement awards—stock options and RSUs—granted to new employees under Vera’s 2024 Inducement Plan at an exercise price of $31.26. Such grants are common for talent recruitment and align with Nasdaq Listing Rule 5635(c)(4). In context, Vera recently highlighted a July 7, 2026 PDUFA date for atacicept and reported a Q1 net loss of $121.0M with $596.8M in cash, so upcoming regulatory and clinical milestones remain the more material drivers to watch.

Key Figures

Inducement stock options: 28,800 shares Inducement RSUs: 14,150 shares Option exercise price: $31.26 per share +5 more

Inducement stock options

28,800 shares

Non-qualified options under 2024 Inducement Plan for 10 new employees

Inducement RSUs

14,150 shares

RSUs under 2024 Inducement Plan for 10 new employees

Option exercise price

$31.26 per share

Grant date June 2, 2026, equal to closing price

Vesting period options

4 years

25% after one year, then monthly over 36 months

Vesting period RSUs

4 years

25% annually starting May 20 or August 20, 2026

Q1 2026 net loss

$121.0M

Reported in Q1 2026 earnings update

Cash & securities

$596.8M

Cash, equivalents and marketable securities as of Mar 31, 2026

PDUFA date

July 7, 2026

Atacicept BLA for IgA nephropathy Priority Review

Historical Context

5 past events · Latest: Jun 02

5 events

1. Jun 02

   Clinical development

   24h Move

   -7.9%

   FDA alignment on earlier ORIGIN Phase 3 eGFR analysis and timelines.

2. May 08

   Inducement grants

   24h Move

   +1.2%

   Stock options and RSUs granted to new employees under inducement plan.

3. May 07

   Earnings update

   24h Move

   -1.9%

   Q1 2026 loss, cash position, and Priority Review with set PDUFA date.

4. May 04

   Conference participation

   24h Move

   +0.9%

   Planned presentation and investor meetings at a major health care conference.

5. Apr 10

   Inducement grants

   24h Move

   -3.0%

   Large batch of stock options and RSUs to 89 new employees.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4), non-qualified stock options, restricted stock units

3 terms

nasdaq listing rule 5635(c)(4) regulatory

"The Compensation Committee approved the awards ... in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

non-qualified stock options financial

"granted inducement awards consisting of non-qualified stock options to purchase 28,800 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

restricted stock units financial

"and restricted stock units (RSUs) underlying 14,150 shares of Class A common stock"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRISBANE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on June 2, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 28,800 shares of Class A common stock and restricted stock units (RSUs) underlying 14,150 shares of Class A common stock to ten (10) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Each stock option granted on June 2, 2026 has an exercise price per share equal to $31.26, Vera Therapeutics’ closing trading price on June 2, 2026. Each stock option will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee’s continued service relationship with Vera Therapeutics through the applicable vesting dates. Each of the RSU awards will vest over four years, with 25% of the underlying shares vesting on each anniversary of either May 20 or August 20, 2026, depending on the start date of the new employee, subject to the new employee’s continued service relationship with Vera Therapeutics through the applicable vesting dates. The awards are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.

About Vera Therapeutics
Vera Therapeutics is a biotechnology company focused on developing treatments for serious immunological diseases. Vera Therapeutics’ mission is to advance treatments that target the source of disease in order to change the standard of care for patients. Vera Therapeutics’ lead product candidate is atacicept, a fusion protein self-administered at home as a subcutaneous once weekly injection that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including immunoglobulin A nephropathy (IgAN) and lupus nephritis. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove clinically meaningful. In addition, Vera Therapeutics holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B-cell-mediated diseases. Vera Therapeutics is also evaluating development of MAU868, a monoclonal antibody designed to neutralize infection with BK virus, which can have devastating consequences in kidney transplant recipients. Vera Therapeutics retains all global developmental and commercial rights to atacicept, VT-109 and MAU868. For more information, please visit www.veratx.com.

For more information, please contact:

Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com

Media Contact:
Debra Charlesworth
Vera Therapeutics
415-854-8051
corporatecommunications@veratx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement equity grants did Vera Therapeutics (VERA) announce on June 5, 2026?

Vera Therapeutics announced equity inducement awards for ten new employees, totaling 28,800 stock options and 14,150 RSUs. According to Vera Therapeutics, these grants were issued under the 2024 Inducement Plan in line with Nasdaq Listing Rule 5635(c)(4).

What is the exercise price of Vera Therapeutics (VERA) inducement stock options granted June 2, 2026?

The inducement stock options have a $31.26 exercise price per share. According to Vera Therapeutics, this price equals the company’s closing trading price on June 2, 2026, when the options were granted to ten new employees.

How do Vera Therapeutics (VERA) inducement stock options vest for new employees?

The inducement stock options vest over four years. According to Vera Therapeutics, 25% of shares vest on the first anniversary of the vesting start date, with the remaining 75% vesting monthly over the following 36 months, subject to continued service.

What is the vesting schedule for Vera Therapeutics (VERA) inducement RSU awards?

The inducement RSUs vest over four years in 25% annual installments. According to Vera Therapeutics, vesting occurs on each anniversary of either May 20 or August 20, 2026, depending on the employee’s start date and continued service.

How many total shares are covered by Vera Therapeutics (VERA) 2026 inducement grants?

The 2026 inducement grants cover 42,950 Class A common shares in total. According to Vera Therapeutics, this includes options to purchase 28,800 shares and RSUs for 14,150 shares issued to ten new employees.

Under which plan were Vera Therapeutics (VERA) 2026 inducement grants issued?

The inducement grants were issued under the 2024 Inducement Plan. According to Vera Therapeutics, the Compensation Committee approved these awards as a material inducement to employment, consistent with Nasdaq Listing Rule 5635(c)(4).